Cantor Fitzgerald Maintains Overweight on Longboard Pharmaceuticals, Raises Price Target to $60
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has maintained an Overweight rating on Longboard Pharmaceuticals (LBPH) and increased the price target from $55 to $60.
January 16, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst reaffirms Overweight rating on LBPH and raises price target to $60, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and growth potential. This can lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100